Connect Biopharma Holdings (CNTB) EBT Margin (2024 - 2026)
Connect Biopharma Holdings' (CNTB) quarterly EBT Margin came in at 622.25% in Q2 2026, up 2613608.0% year-over-year from N/an in Q2 2025, and up 94.57% quarter-over-quarter from 11449.7% in Q1 2026.
Powered by 
Analysis
Connect Biopharma Holdings (CNTB) EBT Margin (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has disclosed EBT Margin across 3 years of filings, most recently posting 622.25% for Q2 2026.
- In Q2 2026, EBT Margin rose 2613608.0% year-over-year to 622.25%; the TTM figure through Jun 2026 stood at 2329.66% (down 5582.0% YoY), while the FY2025 annual figure was 86379.69%, down 8632051.0% from the prior year.
- EBT Margin came in at 622.25% for Q2 2026 at Connect Biopharma Holdings, up from 11449.7% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 622.25% in Q2 2026 to a low of 107118.75% in Q3 2025.
- Average EBT Margin over 3 years is 24710.23%, with a median of 6355.22% recorded in 2024.
- Year-over-year, EBT Margin tumbled 10606715 bps in 2025 and soared 2613608 bps in 2026.
- Over 3 years, EBT Margin stood at 1260.74% in 2024, then slumped by 8396 bps to 107118.75% in 2025, then jumped by 99 bps to 622.25% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 622.25% in Q2 2026, 11449.7% in Q1 2026, and 107118.75% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Connect Biopharma Holdings | 129.86 Mn | 129.86 Mn | - | -622.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -622.25% |
| Mar 31, 2026 | -11,449.70% |
| Sep 30, 2025 | -107,118.75% |
| Jun 30, 2025 | -26,758.33% |
| Dec 31, 2024 | -1,260.74% |
| Sep 30, 2024 | -1,051.60% |